Abstract: Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists, and methods of making and using the foregoing are disclosed.

Abstract: Methods useful for human adapting non-human monoclonal antibodies are disclosed. The methods select candidate human antibody framework sequences from a human germline framework database.

Abstract: Isolated polynucleotides encoding Papio cynocephalus Toll-Like Receptor 3 (Baboon TLR3), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.

Abstract: The present invention relates to at least one improved human GLP-1 mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or specified portion or variant, GLP-1 mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Abstract: Mammalian sRAGE mimetibody polypeptides and nucleic acids are disclosed. Methods of utilizing the polypeptides to reduce or inhibit the binding of RAGE and its ligands and to treat RAGE-related diseases are also disclosed.

Abstract: The invention describes a method for screening antibody producing cell lines for selection of high expressing clones.

Abstract: Isolated polynucleotides encoding Cynomolgus monkey Toll-Like Receptor 3 (cynoTLR3), polypeptides obtainable from expression of these polynucleotides, recombinant cells, methods and uses of these are disclosed.

Abstract: The present invention outlines a novel approach to utilizing the results of genomic sequence information by computer-directed polynucleotide assembly based upon information available in databases such as the human genome database. Specifically, the present invention may be used to select, synthesize and assemble a novel, synthetic target polynucleotide sequence encoding a target polypeptide. The target polynucleotide may encode a target polypeptide that exhibits enhanced or altered biological activity as compared to a model polypeptide encoded by a natural (wild-type) or model polynucleotide sequence.

Abstract: Melanocortin receptor binding mimetibody polypeptides are disclosed. Polynucleotides encoding these polypeptides, cells comprising these polynucleotides or expressing the mimetibodies, and methods of making and using the forgoing are also disclosed.

Abstract: Homo sapiens OCT-2 variant peptide chains are disclosed. Polynucleotides encoding these peptide chains, cells comprising these polynucleotides, and methods of using the forgoing are also disclosed.

Abstract: Isolated polynucleotides encoding Macaca fascicularis ST2L (Cyno ST2L), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.

Abstract: Methods for synthesizing a collection of partially identical polynucleotides are disclosed.

Abstract: The present invention provides to at least one novel human GLP-1 receptor agonist, or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 receptor agonist, or specified portion or variant, GLP-1 receptor agonist, or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including the use of long acting GLP-1 receptor agonists to improve insulin sensitivity or lipid profiles in obesity and related therapeutic and/or diagnostic compositions, methods and devices.

Abstract: Mammalian GLP-2 mimetibodies, polypeptides and nucleic acids are disclosed. Methods of utilizing the mimetibodies and polypeptides to treat GLP-2 related diseases are also disclosed.

Abstract: Novel TNF? antibody polypeptides and nucleic acids are disclosed. Methods of utilizing the polypeptides to treat TNF?-related diseases are also disclosed.

Abstract: HIV gp41 mimetibody polypeptides and encoding polynucleotides are disclosed. Methods of utilizing the polypeptides to reduce or inhibit HIV fusion with a cell membrane and entry into target cells are also disclosed.

Abstract: Toll Like Receptor 3 (TLR3) modulators, such as antibodies, polynucleotides encoding TLR3 antibodies or fragments thereof, and methods of making and using the foregoing are disclosed.

Abstract: Isolated polynucleotides encoding Cynomolgus monkey prostate specific antigen and polypeptides obtainable from the polynucleotides and uses are disclosed.

Abstract: Human Bone Morphogenic Protein 7 (hBMP-7) variant peptide chains, nucleic acids encoding these peptide chains, and methods of making and using the foregoing are disclosed.

Abstract: Chemically defined media compositions for the culture of eukaryotic cells are disclosed. The compositions are useful for eukaryotic cell culture in perfusion bioreactors and other vessels.